TG Therapeutics to Present New Data on BRIUMVI® at 2025 ECTRIMS Annual Meeting

Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 ECTRIMS annual meeting in Barcelona, Spain, from September 24 to 26, 2025. Key highlights include an oral presentation by Dr. Bruce Cree on long-term efficacy and safety results from ULTIMATE I and II studies, along with ePoster presentations on modified dosing regimens and real-world clinical experiences.Reuters

Impact Analysis

So basically, TG Therapeutics is using the ECTRIMS annual meeting as a stage to reinforce BRIUMVI®’s market position in treating relapsing multiple sclerosis. The timing is strategic, given the competitive landscape and recent strong sales growth for BRIUMVI®.Motley Fool The focus on long-term efficacy and safety results from the ULTIMATE I and II studies suggests confidence in the drug’s performance and potential to capture more market share.Reuters What’s interesting is the emphasis on real-world clinical experiences, which could sway healthcare providers and patients towards BRIUMVI® over competitors.Reuters The market might be underestimating the impact of these presentations on TG’s revenue trajectory and competitive edge. I’d read this as a bullish signal for TG Therapeutics, especially if the data resonates well with the audience at ECTRIMS. Keep an eye on any shifts in sentiment or analyst upgrades post-conference.